ClinicalTrials.gg
CompletedNCT01996865MAGNIFYUpdated Jul 10, 2025Results posted

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.

A Phase 3 interventional study of Lenalidomide and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Celgene. Completed at 126 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-10.

Primary conditionLymphoma, Mantle-CellRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Mantle-Cell
Why
  1. The study's title name Lymphoma, Mantle-Cell, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
503
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing lenalidomide in Lymphoma, Mantle-Cell — 5 open to participants now, 8 under way, none of them phase 3. Lenalidomide · Lymphoma, Mantle-Cell.

Enrollment
2nd of 43
503 · median 39
Started
2014
with 1 other
Phase 3
4 of 44
none open now
Registered
24th of 44
by date
Lead sponsor
4 of 44
Celgene

Among the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, this one is the 2nd largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2014, is one of 4 in phase 3, and was the 24th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-cell NHL. Lenalidomide is an immunomodulatory agent with direct and immune-mediated mechanisms of action, as well as clinical activity in NHL. Recent studies in frontline and relapsed/refractory NHL show high activity for lenalidomide plus rituximab (R2), supporting further study of this combination.

Read the detailed description

MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL) who received ≥1 prior therapy and had stage I-IV, measurable disease. \~500 patients are planned for enrollment in 12 cycles of R2 induction, with a projected \~314 patients with ≥SD after induction randomized (1:1) to two maintenance arms. Induction includes oral lenalidomide 20 mg/day, days 1-21 per 28-day cycle (d1-21/28) plus IV rituximab 375 mg/m2, days 1, 8, 15, and 22 of cycle 1 and day 1 of cycles 3, 5, 7, 9, and 11 (28-day cycles). Patients are then randomized to maintenance lenalidomide 10 mg/day, d1-21/28, cycles 13-30, plus rituximab 375 mg/m2, day 1 of cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 (R2, Arm A), or rituximab alone (same schedule, Arm B). Patients receiving R2 maintenance after 18 cycles may continue maintenance lenalidomide monotherapy 10 mg/day, d1-21/28 (per patient and/or investigator discretion), until disease progression as tolerated. The primary endpoint is progression-free survival (per modified 1999 IWG criteria). Secondary endpoints include safety, overall survival, response rates, duration of response, and quality of life (exploratory). Patients will be followed for ≥5 years after the last patient initiated induction therapy. Enrollment in MAGNIFY began in March 2014; as of Jan 2016, 133 patients are enrolled.

03

Conditions studied

  • Lymphoma, Non-Hodgkin

Keywords

  • Lymphoma, Mantle cell Lymphoma, Follicular Lymphoma, Marginal zone Lymphoma, Lenalidomide treatment, rituximab treatment, Non Hodgkins Lymphoma
04

In context

Lymphoma, Mantle-Cell Reclassified

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

This study's enrollment of 503 is above the median of 37 across 1,001 interventional studies indexed under Lymphoma, Mantle-Cell.

Browse Lymphoma, Mantle-Cell studies →

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Compared within Lymphoma, Mantle-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-- Age ≥18 years

  • confirmed Follicular Lymphoma (FL, Grade 1, 2, 3a, or 3b), Transformed FL, Marginal Zone Lymphoma, or Mantle Cell Lymphoma
  • Must have documented , refractory or Progressive Disease after last treatment with systemic therapy
  • Bi-dimensionally
  • (ECOG) Performance status \< 2
  • Adequate bone marrow function
  • Willingness to follow pregnancy precautions

Exclusion criteria

Exclusion Criteria:

  • Histology other than follicular or marginal zone lymphoma or clinical evidence of transformation or Grade 3b follicular lymphoma
  • Any medical condition (other than the underlying lymphoma) that requires chronic use
  • Subjects taking corticosteroids during the last 1 week prior treatment, unless administered at a dose equivalent to \< 20 mg/day of prednisone
  • Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 4 weeks use of radioimmunotherapy within 3 months
  • Known seropositive for or active viral infection with virus (HBV), virus (HCV), (HIV)
  • Known sensitivity or allergy to murine products
  • Presence or history of central nervous system involvement by lymphoma. Subjects who are at a risk for a thromboembolic event and are not willing to take prophylaxis for it
  • Any condition that places the subject at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
503 participants (actual)

Study arms

  • Experimental
    Arm A: Lenalidomide + rituximab followed by lenalidomide

    Induction Period (12 cycles): Lenalidomide 20mg (10 mg if creatinine clearance ≥ 30 mL/min but \< 60mL/min) by mouth (PO) daily (QD) on Days 1 to 21 of every 28-day cycle during cycles 1 through 12 and rituximab 375mg/m\^2 intraveneously (IV) every week in Cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period (lasting 18 Cycles) that includes Lenalidomide 10 mg PO QD on Days 1 to 21 of every 28-day cycle during cycles 13 to 30 and rituximab 375 mg/m\^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29 followed by an optional Maintenance Period (up to Progressive Disease) receiving Lenalidomide 10mg PO QD on Days 1 through 21 of every 28 day cycle until the disease progresses

    Drug: Lenalidomide · Drug: Rituximab

  • Active comparator
    Arm B: Lenalidomide + rituximab followed by rituximab

    Induction Period (12 Cycles): Lenalidomide 20 mg PO QD (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) on Days 1 to 21 of every 28-day cycle during cycles 1 to 12 and rituximab 375 mg/m\^2 IV every week in cycle 1 on Days 1, 8, 15, and 22 and on Day 1 of every 28-day cycle during cycles 3, 5, 7, 9, and 11, followed by a Maintenance Period for 18 Cycles that includes: Rituximab 375 mg/m\^2 IV on Day 1 of every 28-day cycle during cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29

    Drug: Lenalidomide · Drug: Rituximab

Interventions

07

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    Progression free survival (PFS) is defined as the time from the date of first dose of maintenance therapy to the date of the first objective documentation of tumor progression or death due to any cause. Analysis was based on Kaplan Meier estimates. The PFS events were determined using a modification of the IWG 1999 criteria.

    Time frame: From the first dose date of maintenance therapy to objective disease progression or death from any cause, whichever occurs first (up to approximately 432 weeks)

Secondary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) is defined as the time between the first dose date of maintenance therapy and death from any cause. Participants who complete the study and are still alive at the time of the clinical data cutoff date will be censored at the last visit date or the last contact date, whichever is later. Participants who were lost to follow-up prior to the clinical data cut-off date will also be censored at the time of the last contact. Analysis was based on Kaplan Meier estimates and Hazard Ratio (HR).

    Time frame: From the first dose date of maintenance therapy to death from any cause (up to approximately 480 weeks)

  2. Improvement of Response (IOR)

    Improvement of Response (IOR) is the percentage of participants with improved tumor response during the maintenance phase (converted from partial response at end of induction to complete response or complete response unconfirmed as best response) and participants who converted from stable disease at the end of induction period to partial response or better as best response during maintenance phase.

    Time frame: From the first dose date of maintenance therapy to death from any cause (up to approximately 432 weeks)

  3. Overall Response Rate (ORR)

    The overall response rate (ORR) is defined as the percentage of participants with a best response of at least partial response (including complete response, complete response unconfirmed and partial response) after the first dose date of maintenance therapy and prior to any treatment change.

    Time frame: From the first dose date of maintenance therapy up to CR, CRu, PR, or treatment change (up to approximately 432 weeks)

  4. Complete Response Rate (CRR)

    Best Complete Response Rate (CRR), defined as the proportion of participants with a best response of at least CRu (including CR and CRu) after the first dose date of maintenance therapy and prior to any treatment change.

    Time frame: From the first dose date of maintenance therapy up to CR or CRu (up to approximately 432 weeks)

  5. Duration of Response (DOR)

    DOR is from initial response (at least CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change. Analysis was based on Kaplan Meier estimates.

    Time frame: From the initial response (at least PR) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death, whichever occurs first (up to approximately 432 weeks)

  6. Time to Next Anti-lymphoma Treatment

    Time to next anti-lymphoma treatment is defined as the time from the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy. Participants without new treatment therapy will be censored at the last visit. Analysis was based on Kaplan Meier estimates.

    Time frame: From the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy (up to approximately 300 weeks)

  7. Time to Histological Transformation

    Time to histological transformation is defined as from the first dose date of maintenance therapy to the time of histological transformation as measured based on documentation of histological transformation (as assessed by the investigator). Analysis was based on Kaplan Meier estimates. In case of clinical suspicion of transformation, including rapid disease progression, unexpected changes in "B" symptoms or rapidly increasing LDH, a biopsy should be performed. In this clinical trial, histological transformation will be considered disease progression. This endpoint will not be calculated for participants randomized with transformed Follicular Lymphoma (tFL).

    Time frame: From the first dose date of maintenance therapy to the time of histological transformation (up to approximately 432 weeks)

  8. Duration of Complete Response (DOCR)

    Duration of complete response (DOCR) is calculated as the time from the initial response (CR or CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Analysis was based on Kaplan Meier estimates. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change.

    Time frame: From the initial CR/CRu after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death, whichever occurs first (up to approximately 432 weeks)

  9. Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

    Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment.

    Time frame: From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)

  10. Participants Experiencing Adverse Events Related to Vital Signs

    The number of participants who experienced adverse events related to vital sign measurements

    Time frame: From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)

  11. Participants With Grade 3 or Grade 4 Hematology Parameters

    Clinical laboratory values in induction period include any laboratory values that are taken after the first dose date of induction therapy through 28 days after the last dose date of induction therapy or before the first dose date of maintenance therapy, whichever is earlier. Graded according to the NCI CTCAE version 4.03, except for tumor flare reaction, which is accessed using NCI CTCAE version 3.0. Participants with zero maximum grade are excluded.

    Time frame: From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)

  12. Participants With Grade 3 or Grade 4 Serum Chemistry Parameters

    Clinical laboratory values in induction period include any laboratory values that are taken after the first dose date of induction therapy through 28 days after the last dose date of therapy. Graded according to the NCI CTCAE version 4.03, except for tumor flare reaction, which is accessed using NCI CTCAE version 3.0. Participants with zero maximum grade are excluded.

    Time frame: From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)

08

Results

Posted Jul 10, 2025

Participant flow

Induction Period
Participant flow — Induction Period
MilestoneInduction Period: Lenalidomide + RituximabArm A: Lenalidomide + RituximabArm B: Rituximab
Started50300
Treated50000
Completed28400
Not completed21900
Withdrew: Protocol violation100
Withdrew: Progressive disease400
Withdrew: Lost to follow-up1000
Withdrew: Other reasons1300
Withdrew: Adverse event2000
Withdrew: Withdrawal by subject6000
Withdrew: Death11100
Maintenance Period
Participant flow — Maintenance Period
MilestoneInduction Period: Lenalidomide + RituximabArm A: Lenalidomide + RituximabArm B: Rituximab
Started0135132
Treated0134132
Completed07889
Not completed05743
Withdrew: Protocol violation011
Withdrew: Other reasons085
Withdrew: Progressive disease0623
Withdrew: Withdrawal by subject0184
Withdrew: Adverse event077
Withdrew: Death0153
Withdrew: Lost to follow-up020

Outcome measures

PrimaryProgression Free Survival (PFS)

Progression free survival (PFS) is defined as the time from the date of first dose of maintenance therapy to the date of the first objective documentation of tumor progression or death due to any cause. Analysis was based on Kaplan Meier estimates. The PFS events were determined using a modification of the IWG 1999 criteria.

Time frame:
From the first dose date of maintenance therapy to objective disease progression or death from any cause, whichever occurs first (up to approximately 432 weeks)
Reported as:
Median · Weeks
Progression Free Survival (PFS)
WeeksArm A: Lenalidomide + RituximabArm B: Rituximab
Progression Free Survival (PFS)263.1 (166.1 to NA)229.1 (173.7 to NA)
Statistical analysis
  • Arm A: Lenalidomide + Rituximab vs Arm B: Rituximab · Regression, Cox · p = 0.3296 · Hazard ratio (hr): 0.8 · 95% CI 0.6 to 1.2
SecondaryOverall Survival (OS)

Overall Survival (OS) is defined as the time between the first dose date of maintenance therapy and death from any cause. Participants who complete the study and are still alive at the time of the clinical data cutoff date will be censored at the last visit date or the last contact date, whichever is later. Participants who were lost to follow-up prior to the clinical data cut-off date will also be censored at the time of the last contact. Analysis was based on Kaplan Meier estimates and Hazard Ratio (HR).

Time frame:
From the first dose date of maintenance therapy to death from any cause (up to approximately 480 weeks)
Reported as:
Median · Weeks
Overall Survival (OS)
WeeksArm A: Lenalidomide + RituximabArm B: Rituximab
Overall Survival (OS)NA (439.4 to NA)NA (395.7 to NA)
Statistical analysis
  • Arm A: Lenalidomide + Rituximab vs Arm B: Rituximab · Regression, Cox · p = 0.1222 · Hazard ratio (hr): 0.7 · 95% CI 0.4 to 1.1
SecondaryImprovement of Response (IOR)

Improvement of Response (IOR) is the percentage of participants with improved tumor response during the maintenance phase (converted from partial response at end of induction to complete response or complete response unconfirmed as best response) and participants who converted from stable disease at the end of induction period to partial response or better as best response during maintenance phase.

Time frame:
From the first dose date of maintenance therapy to death from any cause (up to approximately 432 weeks)
Reported as:
Number · Percentage of participants
Improvement of Response (IOR)
Percentage of participantsArm A: Lenalidomide + RituximabArm B: Rituximab
Improvement of Response (IOR)20 (13.6 to 27.7)11.4 (6.5 to 18.0)
SecondaryOverall Response Rate (ORR)

The overall response rate (ORR) is defined as the percentage of participants with a best response of at least partial response (including complete response, complete response unconfirmed and partial response) after the first dose date of maintenance therapy and prior to any treatment change.

Time frame:
From the first dose date of maintenance therapy up to CR, CRu, PR, or treatment change (up to approximately 432 weeks)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsArm A: Lenalidomide + RituximabArm B: Rituximab
Overall Response Rate (ORR)85.2 (78.1 to 90.7)79.5 (71.7 to 86.1)
SecondaryComplete Response Rate (CRR)

Best Complete Response Rate (CRR), defined as the proportion of participants with a best response of at least CRu (including CR and CRu) after the first dose date of maintenance therapy and prior to any treatment change.

Time frame:
From the first dose date of maintenance therapy up to CR or CRu (up to approximately 432 weeks)
Reported as:
Number · Percentage of participants
Complete Response Rate (CRR)
Percentage of participantsArm A: Lenalidomide + RituximabArm B: Rituximab
Complete Response Rate (CRR)60.7 (52.0 to 69.0)58.3 (49.4 to 66.8)
SecondaryDuration of Response (DOR)

DOR is from initial response (at least CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change. Analysis was based on Kaplan Meier estimates.

Time frame:
From the initial response (at least PR) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death, whichever occurs first (up to approximately 432 weeks)
Reported as:
Median · Weeks
Duration of Response (DOR)
WeeksArm A: Lenalidomide + RituximabArm B: Rituximab
Duration of Response (DOR)268.3 (168.0 to NA)306.0 (183.7 to NA)
SecondaryTime to Next Anti-lymphoma Treatment

Time to next anti-lymphoma treatment is defined as the time from the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy. Participants without new treatment therapy will be censored at the last visit. Analysis was based on Kaplan Meier estimates.

Time frame:
From the first dose date of maintenance therapy to the time of first documented administration of new anti-lymphoma therapy (up to approximately 300 weeks)
Reported as:
Median · Weeks
Time to Next Anti-lymphoma Treatment
WeeksArm A: Lenalidomide + RituximabArm B: Rituximab
Time to Next Anti-lymphoma TreatmentNA (300.4 to NA)NA (283.4 to NA)
SecondaryTime to Histological Transformation

Time to histological transformation is defined as from the first dose date of maintenance therapy to the time of histological transformation as measured based on documentation of histological transformation (as assessed by the investigator). Analysis was based on Kaplan Meier estimates. In case of clinical suspicion of transformation, including rapid disease progression, unexpected changes in "B" symptoms or rapidly increasing LDH, a biopsy should be performed. In this clinical trial, histological transformation will be considered disease progression. This endpoint will not be calculated for participants randomized with transformed Follicular Lymphoma (tFL).

Time frame:
From the first dose date of maintenance therapy to the time of histological transformation (up to approximately 432 weeks)
Reported as:
Median · Weeks
Time to Histological Transformation
WeeksArm A: Lenalidomide + RituximabArm B: Rituximab
Time to Histological TransformationNA (NA to NA)NA (NA to NA)
SecondaryDuration of Complete Response (DOCR)

Duration of complete response (DOCR) is calculated as the time from the initial response (CR or CRu) after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death. Analysis was based on Kaplan Meier estimates. Participants who have not progressed or died at the time of the clinical data cutoff date will be censored at the last assessment showing no progression. Participants who change treatment without evidence of disease progression will be censored at the last assessment showing no progression prior to treatment change.

Time frame:
From the initial CR/CRu after the first dose date of maintenance therapy and prior to treatment change to documented disease progression or death, whichever occurs first (up to approximately 432 weeks)
Reported as:
Median · Weeks
Duration of Complete Response (DOCR)
WeeksArm A: Lenalidomide + RituximabArm B: Rituximab
Duration of Complete Response (DOCR)298.0 (176.0 to NA)NA (221.1 to NA)
SecondaryParticipants Experiencing Treatment Emergent Adverse Events (TEAEs)

Number of participants experiencing AEs, SAEs, AEs leading to study discontinuation, and AEs of interest (AEIs). An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. SAEs is any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization; results significant disability; or is a congenital anomaly/birth defect. TEAEs are defined as AEs with an onset date on or after the first dose of study treatment up to 30 days after the last dose of study treatment in the study, or if a pre-existing condition worsens in severity or becomes serious after receiving the first dose of study treatment.

Time frame:
From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)
Reported as:
Count of participants · Participants
Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
ParticipantsInduction Period: Lenalidomide + RituximabArm A: Lenalidomide + RituximabArm B: Rituximab
Participants experiencing at least one TEAE499133120
Participants experiencing at least one serious TEAE1725722
SecondaryParticipants Experiencing Adverse Events Related to Vital Signs

The number of participants who experienced adverse events related to vital sign measurements

Time frame:
From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)
Reported as:
Count of participants · Participants
Participants Experiencing Adverse Events Related to Vital Signs
ParticipantsInduction Period: Lenalidomide + RituximabArm A: Lenalidomide + RituximabArm B: Rituximab
Hypertension3496
Hypotension2245
Hypoxia520
SecondaryParticipants With Grade 3 or Grade 4 Hematology Parameters

Clinical laboratory values in induction period include any laboratory values that are taken after the first dose date of induction therapy through 28 days after the last dose date of induction therapy or before the first dose date of maintenance therapy, whichever is earlier. Graded according to the NCI CTCAE version 4.03, except for tumor flare reaction, which is accessed using NCI CTCAE version 3.0. Participants with zero maximum grade are excluded.

Time frame:
From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)
Reported as:
Count of participants · Participants
Participants With Grade 3 or Grade 4 Hematology Parameters
ParticipantsInduction Period: Lenalidomide + RituximabArm A: Lenalidomide + RituximabArm B: Rituximab
Anemia - Grade 33170
Leukopenia - Grade 3101196
Thrombocytopenia - Grade 32921
Neutropenia - Grade 31032410
Lymphopenia - Grade 31263121
Anemia - Grade 4000
Leukopenia - Grade 41750
Thrombocytopenia - Grade 4700
Neutropenia - Grade 494256
Lymphopenia - Grade 420102
SecondaryParticipants With Grade 3 or Grade 4 Serum Chemistry Parameters

Clinical laboratory values in induction period include any laboratory values that are taken after the first dose date of induction therapy through 28 days after the last dose date of therapy. Graded according to the NCI CTCAE version 4.03, except for tumor flare reaction, which is accessed using NCI CTCAE version 3.0. Participants with zero maximum grade are excluded.

Time frame:
From first dose up to 30 days after last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period)
Reported as:
Count of participants · Participants
Participants With Grade 3 or Grade 4 Serum Chemistry Parameters
ParticipantsInduction Period: Lenalidomide + RituximabArm A: Lenalidomide + RituximabArm B: Rituximab
Hypokalemia - Grade 33084
Hyperkalemia- Grade 3401
Hypocalcemia - Grade 3710
Hypercalcemia - Grade 3700
Hypophosphatemia - Grade 31762
Hypercreatininemia - Grade 3310
Hyperuricemia - Grade 3401320
Alanine Aminotransferase Increased - Grade 31430
Aspartate Aminotransferase Increased - Grade 3910
Hyperbilirubinemia - Grade 3531
Hypokalemia - Grade 4400
Hyperkalemia- Grade 4120
Hypocalcemia - Grade 4552
Hypercalcemia - Grade 4350
Hypophosphatemia - Grade 4111
Hypercreatininemia - Grade 4120
Hyperuricemia - Grade 4940
Alanine Aminotransferase Increased - Grade 4000
Aspartate Aminotransferase Increased - Grade 4000
Hyperbilirubinemia - Grade 4110

Adverse events

Collected over Participants were assessed for all-cause mortality from their first dose of study treatment to study completion, (up to approximately 10 years). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 64 weeks for induction period and 427 weeks for maintenance period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Period: Lenalidomide + Rituximab112/500 (22.4%)172/500 (34.4%)491/500 (98.2%)
Arm A: Lenalidomide + Rituximab26/134 (19.4%)57/134 (42.5%)129/134 (96.3%)
Arm B: Rituximab32/132 (24.2%)22/132 (16.7%)106/132 (80.3%)
Most frequent serious events
Showing 10 of 226
Most frequent serious events
EventInduction Period: Lenalidomide + RituximabArm A: Lenalidomide + RituximabArm B: Rituximab
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)8/50010/1345/132
PneumoniaInfections and infestations18/5008/1341/132
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/5005/1341/132
NeutropeniaBlood and lymphatic system disorders15/5003/1340/132
Febrile neutropeniaBlood and lymphatic system disorders14/5001/1341/132
Atrial fibrillationCardiac disorders9/5003/1340/132
PyrexiaGeneral disorders1/5003/1342/132
BronchitisInfections and infestations1/5003/1340/132
CellulitisInfections and infestations5/5003/1340/132
Urinary tract infectionInfections and infestations3/5003/1340/132
Most frequent other events
Showing 10 of 68
Most frequent other events
EventInduction Period: Lenalidomide + RituximabArm A: Lenalidomide + RituximabArm B: Rituximab
FatigueGeneral disorders225/50027/13415/132
NeutropeniaBlood and lymphatic system disorders217/50054/13422/132
DiarrhoeaGastrointestinal disorders176/50056/13411/132
CoughRespiratory, thoracic and mediastinal disorders103/50041/13420/132
NauseaGastrointestinal disorders150/50015/1346/132
ConstipationGastrointestinal disorders146/50012/1342/132
PruritusSkin and subcutaneous tissue disorders96/5002/1343/132
ArthralgiaMusculoskeletal and connective tissue disorders68/50023/13418/132
Upper respiratory tract infectionInfections and infestations65/50022/13414/132
Rash maculo-papularSkin and subcutaneous tissue disorders82/5006/1341/132

Baseline characteristics

All participants started in the induction and maintenance periods and are accounted for in this arm.

Age, Categorical
Age, Categorical(Participants)Overall Study
<=18 years0
Between 18 and 65 years209
>=65 years294
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female215
Male288
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino33
Not Hispanic or Latino463
Unknown or Not Reported7
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native1
Asian4
Native Hawaiian or Other Pacific Islander1
Black or African American17
White468
More than one race0
Unknown or Not Reported12
09

Study locations

126 sites
  • Local Institution - 055
    Tucson, Arizona 85710, United States
  • Local Institution - 077
    Little Rock, Arkansas 72205, United States
  • Local Institution - 079
    Berkeley, California 94704, United States
  • Local Institution - 142
    Concord, California 94520, United States
  • Bay Area Cancer Research Group, LLC
    Pleasant Hill, California 94523, United States
  • Sutter Hematology and Oncology
    Sacramento, California 95816, United States
  • Local Institution - 032
    San Diego, California 92123, United States
  • Local Institution - 130
    Santa Barbara, California 93105, United States
  • Local Institution - 052
    Boulder, Colorado 80303, United States
  • Local Institution - 106
    Denver, Colorado 80220, United States
  • Colorado Cancer Research Program
    Denver, Colorado 80222, United States
  • Local Institution - 062
    Glenwood Springs, Colorado 81601, United States
  • Praxair Cancer Center Danbury
    Danbury, Connecticut 06810, United States
  • Medical Oncology and Blood Disorders, LLP
    Manchester, Connecticut 06040, United States
  • Local Institution - 041
    Norwalk, Connecticut 06851, United States
  • Hematology Oncology Associates, PC
    Stamford, Connecticut 06902, United States
  • Local Institution - 149
    Trumbull, Connecticut 06611, United States
  • Local Institution - 116
    Waterbury, Connecticut 067014, United States
  • Local Institution - 068
    Fleming Island, Florida 32003, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Local Institution - 054
    Ocala, Florida 34474, United States
  • Local Institution - 114
    Pensacola, Florida 32504, United States
  • Local Institution - 011
    Marietta, Georgia 30060, United States
  • Local Institution - 083
    Newnan, Georgia 30265, United States
  • Local Institution - 108
    Elk Grove Village, Illinois 60007, United States
  • United States Department of Veterans Affairs - VA Great Lakes Health Care System - Edward Hines Jr
    Hines, Illinois 60141, United States
  • Local Institution - 159
    Hinsdale, Illinois 60521, United States
  • Local Institution - 056
    Niles, Illinois 60714, United States
  • Local Institution - 028
    Park Ridge, Illinois 60068, United States
  • Orchard Healthcare Research Inc.
    Skokie, Illinois 60077, United States
  • American Health Network of Indiana, LLC
    New Albany, Indiana 47150, United States
  • McFarland Clinic
    Ames, Iowa 50010, United States
  • Siouxland Hematology-Oncology Associates, LLP
    Sioux City, Iowa 51101-1733, United States
  • Cedar Valley Medical Specialists
    Waterloo, Iowa 50701, United States
  • Local Institution - 019
    Fairway, Kansas 66205, United States
  • Local Institution - 350
    Great Bend, Kansas 67530, United States
  • Kentucky Cancer Clinic
    Hazard, Kentucky 41701, United States
  • Local Institution - 138
    Louisville, Kentucky 40207, United States
  • Local Institution - 143
    Waterville, Maine 04901, United States
  • Anne Arundel Medical Center
    Annapolis, Maryland 21401, United States
  • Local Institution - 030
    Baltimore, Maryland 21204, United States
  • Associates Of Oncology/Hematology, P.C.
    Rockville, Maryland 20850, United States
  • Local Institution - 051
    Ann Arbor, Michigan 48106, United States
  • Local Institution - 033
    Lansing, Michigan 48912, United States
  • Local Institution - 164
    Rochester, Minnesota 55905, United States
  • Local Institution - 050
    Bolivar, Missouri 65613, United States
  • Local Institution - 103
    Columbia, Missouri 65212, United States
  • Local Institution - 013
    Springfield, Missouri 65804, United States
  • Local Institution - 042
    St Louis, Missouri 63110, United States
  • Local Institution - 003
    Lincoln, Nebraska 68510, United States
  • Local Institution - 098
    Lebanon, New Hampshire 03756, United States
  • Summit Medical Group Overlook Oncology Center
    Berkeley Heights, New Jersey 07922, United States
  • Veterans Affairs New Jersey Health Care System
    East Orange, New Jersey 07018, United States
  • Local Institution - 080
    Englewood, New Jersey 07631, United States
  • Local Institution - 025
    Mount Holly, New Jersey 08060, United States
  • Saint Peter'S University Hospital
    New Brunswick, New Jersey 08901, United States
  • Brookdale University Hospital and Medical Center
    Brooklyn, New York 11212, United States
  • C.R. Wood Cancer Center at Glens Falls Hospital
    Glens Falls, New York 12801, United States
  • Broome Oncology, LLC
    Johnson City, New York 13790, United States
  • Local Institution - 152
    Lake Success, New York 11042, United States
  • Local Institution - 023
    Kinston, North Carolina 28501-1584, United States
  • Local Institution - 039
    Raleigh, North Carolina 27607, United States
  • Summa Health System Akron City Hospital Laboratory
    Akron, Ohio 44202, United States
  • Aultman Hospital
    Canton, Ohio 44710, United States
  • Local Institution - 161
    Cincinnati, Ohio 45242, United States
  • Local Institution - 047
    Cleveland, Ohio 44109, United States
  • Local Institution - 045
    Columbus, Ohio 43219, United States
  • Toledo Clinic Cancer Center
    Toledo, Ohio 43623, United States
  • Local Institution - 037
    Oklahoma City, Oklahoma 73104, United States
  • Local Institution - 059
    Eugene, Oregon 97401, United States
  • Hematology Oncology Associates, P.C.
    Medford, Oregon 97504, United States
  • Local Institution - 073
    Greenville, South Carolina 29615, United States
  • Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute
    Spartanburg, South Carolina 29303, United States
  • Rapid City Regional Hospital
    Rapid City, South Dakota 57701, United States
  • Local Institution - 153
    Sioux Falls, South Dakota 57105, United States
  • Baptist Cancer Center
    Memphis, Tennessee 38104, United States
  • Local Institution - 076
    Memphis, Tennessee 38104, United States
  • Local Institution - 166
    Amarillo, Texas 79106, United States
  • Arlington Cancer Center
    Arlington, Texas 76012, United States
  • Texas Oncology-Arlington South
    Arlington, Texas 76014, United States
  • Local Institution - 105
    Dallas, Texas 75230, United States
  • Local Institution - 026
    Houston, Texas 77030, United States
  • Local Institution - 067
    Houston, Texas 77030, United States
  • Local Institution - 008
    Houston, Texas 77090, United States
  • Local Institution - 021
    Plano, Texas 75093, United States
  • Local Institution - 071
    Round Rock, Texas 78681, United States
  • Local Institution - 070
    San Antonio, Texas 78217, United States
  • Local Institution - 058
    San Antonio, Texas 78240, United States
  • Local Institution - 111
    Temple, Texas 66205, United States
  • Local Institution - 094
    Tyler, Texas 75701, United States
  • Local Institution - 163
    Tyler, Texas 75702, United States
  • Local Institution - 057
    Webster, Texas 77598-4420, United States
  • Local Institution - 090
    Salt Lake City, Utah 84106, United States
  • Rutland Regional Medical Center
    Rutland, Vermont 05701, United States
  • Local Institution - 053
    Christiansburg, Virginia 24073, United States
  • Local Institution - 129
    Fort Belvoir, Virginia 22060, United States
  • Local Institution - 081
    Norfolk, Virginia 23502, United States
  • Cancer Treatment Center of America
    Portsmouth, Virginia 23704, United States
  • PeaceHealth St. Joseph Medical Center
    Bellingham, Washington 98225, United States
  • Local Institution - 049
    Gig Harbor, Washington 98332, United States

Showing the first 100 of 126 sites across 3 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabecadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21. PubMed 30897038 ↗
  • Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH. Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. Br J Haematol. 2019 Jun;185(5):874-882. doi: 10.1111/bjh.15843. Epub 2019 Mar 28. PubMed 30919940 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in May 2024, 121 months.

Results were first posted in Jul 2025, 1 year 1 month after primary completion.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 121 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2013
First posted
Nov 27, 2013
StartActual
Apr 1, 2014
Primary completionActual
May 11, 2024
CompletionActual
Sep 17, 2024
Results first posted
Jul 10, 2025
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01996865
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 27, 2013
Start date
Apr 1, 2014
Primary completion
May 11, 2024
Completion
Sep 17, 2024
Results posted
Jul 10, 2025
Last update
Jul 10, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Rituximab

Start the discussion